Thermo Fisher Scientific INC 8-K filings

Thermo Fisher Scientific announced robust second quarter 2026 financial results, with revenue up 10% and adjusted EPS growing 13%, driven by strengthening end markets and strategic execution.

Thermo Fisher Scientific Inc. held its annual shareholder meeting on May 20, 2026, where directors were elected and the company's auditor was ratified, though a proposal on executive compensation was not approved.

Thermo Fisher Scientific reported strong first quarter 2026 financial results, with revenue growing 6% to $11.01 billion and GAAP diluted EPS increasing 11% to $4.43.

Thermo Fisher Scientific announced the completion of its acquisition of Clario Holdings, Inc. for $8.875 billion in cash, strengthening its clinical research offerings.

Thermo Fisher Scientific Inc. issued $3.8 billion in senior notes across four series to fund a significant acquisition and for general corporate purposes.

Thermo Fisher Scientific announced robust financial results for Q4 and full year 2025, driven by strategic acquisitions and product innovation.

Thermo Fisher Scientific Inc. announced significant changes to its executive leadership team, including the departure of two Executive Vice Presidents and new roles for existing leaders, effective March 2026.

Thermo Fisher Scientific's finance subsidiary successfully issued €2.1 billion in new senior notes, backed by the parent company, for general corporate purposes.

Thermo Fisher Scientific announced a definitive agreement to acquire Clario Holdings, Inc. for approximately $8.875 billion in cash, enhancing its clinical trial endpoint data solutions.

Thermo Fisher Scientific reported robust third-quarter 2025 financial results, with revenue growth and significant adjusted EPS increase, driven by strategic acquisitions and product innovations.

Thermo Fisher Scientific Inc. successfully issued $2.5 billion in new senior unsecured notes across four tranches with maturities ranging from 2031 to 2037 to fund general corporate purposes.

Thermo Fisher Scientific has completed its $4.0 billion cash acquisition of Solventum's Purification & Filtration business, enhancing its bioprocessing and industrial market presence.

Thermo Fisher Scientific Inc. announced the upcoming retirement of its Chief Financial Officer, Stephen Williamson, and the appointment of James R. Meyer as his successor, effective March 1, 2026.

Thermo Fisher Scientific announced its second quarter 2025 financial results, reporting 3% revenue growth and 6% GAAP diluted EPS growth, alongside strategic advancements in product innovation and a key acquisition.

Thermo Fisher Scientific Inc. announced the results of its 2025 Annual Meeting, where shareholders re-elected all director nominees but did not approve the advisory proposal on executive compensation.

Thermo Fisher Scientific grants a 5-year cliff vesting performance-based restricted stock unit award to CEO Marc Casper to incentivize long-term shareholder value growth and secure his leadership through at least May 2030.

Thermo Fisher Scientific announced a slight increase in revenue and a rise in earnings per share for the first quarter of 2025, driven by its growth strategy and operational excellence.

Thermo Fisher Scientific has agreed to acquire Solventum Corporation's purification and filtration business for approximately $4.1 billion in cash, with the transaction expected to close by the end of 2025.

Thermo Fisher Scientific expands its board to twelve members with the appointment of seasoned healthcare executive Karen S. Lynch.

Thermo Fisher Scientific reported a flat full year revenue but a strong fourth quarter with 5% growth, driven by new product launches and strategic partnerships.

Thermo Fisher Scientific announced flat revenue growth for the third quarter of 2024 compared to the same period last year, while raising its full-year adjusted EPS guidance.

Thermo Fisher Scientific announced its second quarter 2024 results, showing a slight revenue decline but increased earnings per share, and raised its full-year guidance.

Thermo Fisher Scientific successfully concludes its tender offer to acquire all outstanding shares and American Depositary Receipts of Olink Holding AB.

Thermo Fisher Scientific held its annual meeting on May 22, 2024, where shareholders elected directors, approved executive compensation, ratified the appointment of auditors, and voted on a shareholder proposal.

Thermo Fisher Scientific announced its first quarter 2024 results, showing a revenue decrease but increased earnings per share, and raised its full-year guidance.

Thermo Fisher Scientific's fourth-quarter revenue declined by 5% year-over-year, while adjusted EPS increased by 5%, and the company provided its 2024 financial guidance.